Association of the British Pharmaceutical Industry

Association of the British Pharmaceutical Industry
Name	Association of the British Pharmaceutical Industry
Native name	ABPI
Formation	1891
Headquarters	London
Region served	United Kingdom
Leader title	Chief Executive
Leader name	Richard Torbett

Association of the British Pharmaceutical Industry is a trade association representing pharmaceutical companies operating in the United Kingdom. It acts as an industry voice on health policy and interacts with regulatory bodies, insurers, and patient groups. The association engages with legislators, such as members of the Parliament of the United Kingdom, and international institutions including the European Medicines Agency and the World Health Organization.

History

Founded in the late 19th century, the organization developed alongside firms such as GlaxoSmithKline, AstraZeneca, Pfizer, and Roche. During the 20th century it navigated events including the World War I pharmaceutical shortages and the post-World War II creation of the National Health Service (United Kingdom), adapting lobbying and compliance activity around landmark statutes like the Medicines Act 1968. In the 1990s and 2000s the association engaged with processes at the European Commission and the European Medicines Agency over regulatory harmonization and intellectual property frameworks influenced by agreements such as the Trade-Related Aspects of Intellectual Property Rights. Recent decades saw responses to crises linked to pandemics referenced alongside institutions like Public Health England, National Institute for Health and Care Excellence, and multinational collaborations involving Bill & Melinda Gates Foundation and Wellcome Trust.

Structure and Governance

The association is governed by a board and executive leadership influenced by major corporate members such as Novartis, Merck & Co., Sanofi, and Johnson & Johnson. Its structure includes policy, legal, and compliance committees that liaise with regulators like the Medicines and Healthcare products Regulatory Agency and advisory bodies including National Institute for Health and Care Excellence and the British Medical Association. Senior staff have previously transitioned between roles at institutions such as the Department of Health and Social Care, House of Commons, and academic centers like University College London and King's College London.

Membership and Funding

Membership comprises multinational corporations, mid-sized firms, and smaller biotechnology companies such as Genzyme and Biogen. Funding sources include membership subscriptions, training services, and paid guidance to members; these financial relationships mirror practices seen in associations like the American Medical Association and European Federation of Pharmaceutical Industries and Associations. The association has disclosed collaborations and sponsored events with charities and foundations including Cancer Research UK and corporate partners such as Eli Lilly and Company and Bayer.

Activities and Advocacy

The association conducts policy advocacy before bodies like the UK Parliament, Scottish Government, and Welsh Government, and engages in campaigning on matters that touch institutions such as NHS England and the European Commission. It publishes guidance on interactions among pharmaceutical firms, healthcare professionals affiliated with Royal College of Physicians and Royal College of General Practitioners, and supports initiatives on research collaborations with universities including University of Oxford and University of Cambridge. The group organizes conferences featuring speakers from organizations like GlaxoSmithKline, AstraZeneca, and regulators including the Medicines and Healthcare products Regulatory Agency, and it contributes to procurement discussions involving bodies such as Crown Commercial Service.

Industry Standards and Codes

The association maintains a code of practice for promotion and interaction with healthcare professionals and patient organizations, comparable to frameworks used by the International Committee of Medical Journal Editors and industry groups like the European Federation of Pharmaceutical Industries and Associations. Its code intersects with legal instruments such as the Bribery Act 2010 and compliance expectations from regulators including the Competition and Markets Authority and the Advertising Standards Authority. Training and audit functions align with standards found in corporate governance guides like the UK Corporate Governance Code.

Controversies and Criticism

The association has faced criticism for its lobbying on pricing and intellectual property issues involving institutions such as NHS England and debates in the House of Commons Health and Social Care Select Committee. Critics have cited concerns similar to those raised in controversies around GlaxoSmithKline and Pfizer regarding transparency, payments to healthcare professionals connected to Royal College of Surgeons of England and patient groups, and debates over access to medicines invoked by organizations like Médecins Sans Frontières. Scrutiny has involved media outlets including BBC and regulatory inquiries with reference to international examples such as the US Food and Drug Administration and cases considered by the Competition and Markets Authority.

Category:Pharmaceutical trade associations Category:Health in the United Kingdom